/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
India’s largest pharma company has caught investors’ fancy and a lot of it is due to founder Dilip Shanghvi’s need to take a different path.
Editor's note: Sun Pharmaceutical Industries’s market capitalization is back at Rs 240,000 crore. That’s just 12% shy of its best ever market capitalization of Rs 269,000 crore, which it hit in March 2015, making its founder Dilip Shanghvi India’s richest person for a brief while before Reliance Industries’s Mukesh Ambani took back the crown. What makes the Sun Pharma stock stand out is that it has gained 18.3% in the last one year, at a time when the healthcare industry, represented by the BSE Healthcare index, fell 11.85%. Sun Pharma has also significantly outperformed the broader Nifty 50, which has risen 2.4% in the same time. The good run is likely to continue for India’s largest pharma company, as most analysts are upbeat about its prospects in the year ahead, even as they forecast a poor run for the pharma sector as a whole. After recovering to its pre-COVID levels in April 2021, the SunPharma stock has only gained ground thereafter, and is now close to its seven-year high. For the 2021-22 financial year, the company’s operating profits stood at Rs 10,258 …
Who’s going to lead the IPO party, what’s going to drive the market, where are some of the leading businesses headed, and more.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
